S

ST Pharm Co Ltd
KOSDAQ:237690

Watchlist Manager
ST Pharm Co Ltd
KOSDAQ:237690
Watchlist
Price: 139 700 KRW 16.32% Market Closed
Market Cap: 2.9T KRW

Net Margin

11.6%
Current
Improving
by 2.7%
vs 3-y average of 8.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
11.6%
=
Net Income
₩36.9B
/
Revenue
₩318.3B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
11.6%
=
Net Income
₩36.9B
/
Revenue
₩318.3B

Peer Comparison

Country Company Market Cap Net
Margin
KR
ST Pharm Co Ltd
KOSDAQ:237690
2.4T KRW
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
241.5B USD
Loading...
US
Danaher Corp
NYSE:DHR
169.6B USD
Loading...
CH
Lonza Group AG
SIX:LONN
38.1B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.7B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
280.3B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
39.3B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
83.2T KRW
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
29.4B USD
Loading...
US
Waters Corp
NYSE:WAT
23.8B USD
Loading...

Market Distribution

Higher than 84% of companies in Korea
Percentile
84th
Based on 2 632 companies
84th percentile
11.6%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

ST Pharm Co Ltd
Glance View

Nestled in the bustling metropolis of Seoul, South Korea, ST Pharm Co Ltd. operates as a dynamic player within the global pharmaceutical industry. Established initially to meet the burgeoning demands of the local pharmaceutical market, the company has slowly carved out a niche for itself in the global arena. With a deft focus on the development and manufacture of active pharmaceutical ingredients (APIs), ST Pharm now sets its sights on becoming a central figure in the synthesis of high-value APIs used in therapies including antivirals and oncology treatments. This focus isn't merely driven by opportunity; it's underpinned by a dedicated commitment to cutting-edge research and development. The company has invested heavily in state-of-the-art facilities and nurtures a team of seasoned scientists who remain at the forefront of innovation. ST Pharm makes its revenue by mastering the art of efficient and reliable API production. By optimizing their production processes, they can offer a competitive edge—delivering high-quality products at scale. The company isn't solely interested in the immediate gains of API manufacture; it also sees potential in providing customized solutions to its diverse clientele, which spans multinational pharmaceutical giants to nimble biotech startups. Partnerships and collaborations have become crucial strategies for ST Pharm, facilitating an exchange of innovation and expertise that keeps them relevant and forward-thinking. In this regard, their business model elegantly balances between standardized API production and bespoke chemical solutions, ensuring a steady revenue stream while opening doors to future advancements in pharmaceutical science.

ST Pharm Co Ltd Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
11.6%
=
Net Income
₩36.9B
/
Revenue
₩318.3B
What is ST Pharm Co Ltd's current Net Margin?

The current Net Margin for ST Pharm Co Ltd is 11.6%, which is above its 3-year median of 8.9%.

How has Net Margin changed over time?

Over the last 3 years, ST Pharm Co Ltd’s Net Margin has increased from 5.5% to 11.6%. During this period, it reached a low of 4.4% on Sep 30, 2023 and a high of 12.7% on Dec 31, 2024.

Back to Top